Dr. John Cush RheumNow
4 years 2 months ago
EMA has approved Secukinumab for the expanded approvals for use in pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) . Approvals based on the JUNIPERA trial, showing reduced the risk of flare & Dz activity w/ SEC https://t.co/fN01V1PBfY https://t.co/UgULLHunky
Dr. John Cush RheumNow
4 years 2 months ago
Exercise and fibromyalgia? Metanalysis of 18 studies & 1184 pts, comparing aerobic, resistance & stretching. All 3 had large & significant effect on pain (not diff from each other); also improves QOL (possibly depression) https://t.co/jVpLXN5oTw https://t.co/si1HjpP0wY
Dr. John Cush RheumNow
4 years 2 months ago
Dr. Baraf is a giant in the rheumatology community ! A nnovative researcher, grand teacher, & masterful clinician make him memorable; but most of all - he's a great friend and kind man! Standing-O for Herb! https://t.co/UREDeSyGRJ
The US Preventive Services Task Force (USPSTF) has updated its recommendations regarding the efficacy of supplements or multivitamins for reducing the risk of cardiovascular disease, cancer, and mortality in the general adult population.
Dr. John Cush RheumNow
4 years 2 months ago
Of the Top 20 most expensive drugs in USA in 2022, only two are for rheumatic reasons. Unfortunately both are for ACTH preparations, once cheap, now devastatingly expensive: #11 Acthar Gel ($41,459/month) & #19 Cortrophin Gel ($30,083) https://t.co/avUZNVnHRp https://t.co/mXLhD8vJ6A
Pooled data from two large ixekizumab (IXE) trials show that male patients had greater clinical responses than did female patients with psoriatic arthritis are largely unexplored. Reasons for this differential treatment responses to an interleukin-17A inhibitor (IXE) between male and female patients is unexplained.
Dr. John Cush RheumNow
4 years 2 months ago
Study of new onset #RA & undiff arthritis pts starting Rx 2005-2010; mean F/U 104 mos, 11% died. Steroids (<7.5/d) given to 44% initially, ultimately 57% w/ 20% recv >7.5/d. Steroids did not increase mortality (HR 1.35 ; 0.74, 2.47) or hospitalization https://t.co/KNpobs1UwH https://t.co/sjddMBKOeE
Oren Gottfried, MD OGdukeneurosurg
4 years 2 months ago
A reflex slide I put together for you. https://t.co/HMumN7WaJY
Sarah Lyon sarahthelyon
4 years 2 months ago
Renal Tubular Disorders #NephTwitter #MedEd #MedDoodles https://t.co/KiCuEaDGrR
Dr. John Cush RheumNow
4 years 2 months ago
It's time to exonerate methotrexate in causing or exacerbating fibrotic interstitial lung disease in #RA patients https://t.co/AuEIWn8Pc4 https://t.co/razVTF6fFX
Dr. John Cush RheumNow
4 years 2 months ago
Simultaneous Versus Staged Knee Arthoplasty?
There are an estimated 900,000 knee replacements (TKR) performed in the U.S. every year. This number is up from 754,000 TKRs in 2017, according to the Agency for Healthcare Research and Quality.
https://t.co/KuLEaI3r0d https://t.co/0q1RBsDwEM
Dr. John Cush RheumNow
4 years 2 months ago
FDA approved Abbvies risakizumab-rzaa (Skyrizi) as the 1st interleukin-23 inhibitor for use in adults with moderately to severely active Crohn's disease (600 mg IV at wk 0, 4, 8, &q8wk @ 360 mg SC). Approval based on ADVANCE, MOTIVATE & FORTIFY RCTs https://t.co/OMYNB1yr2R https://t.co/QMn9GWlYm9
